Journal
CANCER LETTERS
Volume 326, Issue 1, Pages 69-78Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.07.023
Keywords
CAM assay; Sarcoma; Targeted agents; Xenograft model; Angiogenesis
Categories
Funding
- Depuy Spine Belgium, a division of Johnson & Johnson Medical company
Ask authors/readers for more resources
The chick chorioallantoic membrane (CAM) assay was used to evaluate whether xenotransplanted sarcomas retain the histological characteristics and functional behavior of the original tumors. Metabolically active tumor tissue, identified by dynamic-contrast MRI, from 28 patients with a bone or soft-tissue tumors was applied to the CAM. Angiogenesis and graft and host behaviors were evaluated. The essential features and immunohistochemical characteristics of the original tumors were maintained, illustrating the diversity of sarcomas. Graft viability was inversely related to patient survival, but longer follow-up and more patients are needed to relate tumor graft behavior to natural history. We conclude that the CAM assay is a potential prognostic and predictive preclinical xenograft model for tumors that are difficult to culture in vitro, such as sarcomas; therefore, the use of the CAM assay may facilitate personalized medicine. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available